Lecanemab (Leqembi)

Migration, Crosslink

📖

Lecanemab (Leqembi)

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-lecanemab

📖 Wiki Page

therapeutic1394 wordssynced 2026-04-02

Lecanemab (Leqembi)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Lecanemab (Leqembi)</th>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Result</td>
</tr>
<tr>
<td class="label">Primary (ADCOMS at 18 months)</td>
<td>Dose-dependent reduction observed</td>
</tr>
<tr>
<td class="label">Brain amyloid reduction</td>
<td>Dose-dependent clearance</td>
</tr>
<tr>
<td class="label">Highest dose (10 mg/kg biweekly)</td>
<td>Slower clinical decline</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Change</td>
</tr>
<tr>
<td class="label">Brain amyloid (Centiloid)</td>
<td>Reduced from 53 to 10</td>
</tr>
<tr>
<td class="label">CSF p-tau181</td>
<td>Reduced significantly</td>
</tr>
<tr>
<td class="label">CSF t-[tau](/proteins/tau)</td>
<td>Reduced significantly</td>
</tr>
<tr>
<td class="label">Amyloid-related imaging abnormalities (ARIA)</td>
<td>Slight increase</td>
</tr>
<tr>
<td class="label">ARIA Type</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">ARIA-E (edema)</td>
<td>12.6%</td>
</tr>
<tr>
<td class="label">ARIA-H (hemorrhage)</td>
<td>17.3%</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Protofibrils</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>10 mg/kg biweekly</td>
</tr>
<tr>
<td class="label">Amyloid reduction</td>
<td>~80%</td>
</tr>
<tr>
<td class="

...

Lecanemab (Leqembi)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Lecanemab (Leqembi)</th>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Result</td>
</tr>
<tr>
<td class="label">Primary (ADCOMS at 18 months)</td>
<td>Dose-dependent reduction observed</td>
</tr>
<tr>
<td class="label">Brain amyloid reduction</td>
<td>Dose-dependent clearance</td>
</tr>
<tr>
<td class="label">Highest dose (10 mg/kg biweekly)</td>
<td>Slower clinical decline</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Change</td>
</tr>
<tr>
<td class="label">Brain amyloid (Centiloid)</td>
<td>Reduced from 53 to 10</td>
</tr>
<tr>
<td class="label">CSF p-tau181</td>
<td>Reduced significantly</td>
</tr>
<tr>
<td class="label">CSF t-[tau](/proteins/tau)</td>
<td>Reduced significantly</td>
</tr>
<tr>
<td class="label">Amyloid-related imaging abnormalities (ARIA)</td>
<td>Slight increase</td>
</tr>
<tr>
<td class="label">ARIA Type</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">ARIA-E (edema)</td>
<td>12.6%</td>
</tr>
<tr>
<td class="label">ARIA-H (hemorrhage)</td>
<td>17.3%</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Protofibrils</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>10 mg/kg biweekly</td>
</tr>
<tr>
<td class="label">Amyloid reduction</td>
<td>~80%</td>
</tr>
<tr>
<td class="label">CDR-SB benefit</td>
<td>0.45</td>
</tr>
<tr>
<td class="label">ARIA-E rate</td>
<td>12.6%</td>
</tr>
</table>

Overview

[Lecanemab](/therapeutics/lecanemab) (brand name Leqembi; development code BAN2401) is a humanized IgG1 monoclonal antibody developed by [Eisai](https://www.eisai.com) and [Biogen](https://www.biogen.com) for the treatment of early Alzheimer's Disease. It represents a significant advancement in disease-modifying therapy for Alzheimer's Disease by targeting protofibrils of [Amyloid-Beta](/proteins/amyloid-beta) (Aβ)[@mcdade2022]. Approved in 2023, Leqembi became the first amyloid-targeting antibody to receive traditional FDA approval based on Phase III clinical trial data.

Introduction

[Lecanemab](/entities/lecanemab) binds with high affinity to soluble [Aβ](/proteins/amyloid-beta-protein) protofibrils, which are highly toxic intermediate aggregates in the amyloid cascade. Unlike earlier anti-amyloid antibodies that primarily targeted monomers or mature plaques, lecanemab's specificity for protofibrils allows it to intercept the most toxic form of Aβ before it can cause widespread neuronal damage[@ishii2022].

The approval of lecanemab marked a paradigm shift in Alzheimer's treatment, demonstrating that removing amyloid plaques can slow cognitive decline in early-stage patients. This validation of the amyloid cascade hypothesis has spurred further development of anti-amyloid and anti-[tau](/proteins/tau) therapeutics.

Mechanism of Action

Amyloid-Beta Targeting

Lecanemab's mechanism differs from other anti-amyloid antibodies:

Selectively targets Aβ protofibrils over monomers - protofibrils are soluble aggregates that are 10-100x more toxic than monomers
Higher affinity for Aβ than aducanumab or donanemab - KD of ~10^(-10) M for protofibrils
Reduces both soluble and insoluble Aβ plaque burden in the brain
Prevents spread of toxic aggregates by neutralizing circulating protofibrils

Clearance Mechanisms

The antibody-Aβ complex is cleared through multiple pathways[@van2023]:

Microglial-mediated phagocytosis: Fcγ receptor engagement triggers [microglia](/cell-types/microglia) to engulf antibody-Aβ complexes

Peripheral sink effect: Binding to plasma Aβ creates gradient drawing brain Aβ into circulation

Direct plaque disaggregation: May destabilize existing plaque structure

Enhanced CSF Aβ42: Reflects reduced brain Aβ production or increased clearance

Clinical Development

Phase II Clinical Trial (Study 201)

The Phase IIb trial enrolled 856 patients with early AD (MCI due to AD or mild AD dementia)[@cummings2022]:

This study established the optimal dosing regimen of 10 mg/kg biweekly for the Phase III program.

Phase III Clarity Trial

The Phase III Clarity-AD trial enrolled 1,795 patients with early AD[@eisai2022]:

Primary endpoint: Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) at 18 months
Result: Met primary and all key secondary endpoints
Efficacy: 27% slower clinical decline vs. placebo (difference of 0.45 CDR-SB points)
Amyloid reduction: Centiloid reduction from 53 to 10 (≈81% reduction)
Benefits observed: Across all biomarker and clinical subgroups

Efficacy

Cognitive Outcomes

Lecanemab demonstrated clinically meaningful benefits:

Reduced CDR-SB decline by 0.45 points at 18 months vs. placebo
Benefits emerged as early as 6 months of treatment
Effects sustained throughout the 18-month treatment period
Greater benefit with longer treatment duration in open-label extension

Biomarker Effects

Subgroup Analyses

Consistent benefits across [APOE](/proteins/apoe-protein) ε4 carriers and non-carriers
Similar efficacy in MCI and mild dementia subgroups
Benefits regardless of baseline tau PET status

Safety Profile

Most cases mild to moderate in severity
Incidence highest in first 12 weeks of treatment
Monitoring required with MRI at baseline and regular intervals

ARIA Monitoring Guidelines

Baseline: MRI within 6 months before first infusion, [APOE](/genes/apoe) testing recommended.

MRI Schedule: Week 12, Week 24, then annually. Additional scans if symptoms develop.

Risk Factors:

APOE ε4 carriers (especially homozygotes) have higher ARIA risk
Consider more frequent monitoring for high-risk patients

Monitoring Checklist:

Report severe headache, confusion, visual changes, or seizures immediately
Hold drug for moderate-severe ARIA-E
Consider steroids for severe cases
Discontinue if recurrent severe ARIA

Other Adverse Events

Infusion-related reactions: 20.4% vs. 3.4% placebo
Most reactions mild, managed with premedication
No increased mortality signal compared to placebo
Generally manageable with standard protocols

Comparison with Other Anti-Amyloid Therapies

Regulatory Status

Approvals

United States: Full FDA approval (January 2023), traditional approval (July 2023)
Japan: Approved (January 2023)
South Korea: Approved (May 2023)
China: Approved (October 2023)
EU: Recommended for approval (November 2023)
UK: Under review

Indication

Early Alzheimer's Disease (MCI due to AD or mild dementia) with confirmed amyloid pathology via PET scan or CSF biomarkers.

Future Directions

Combination Therapies

Investigational approaches include:

Combination with tau-targeting agents (e.g., anti-tau antibodies)
Combination with neuroprotective compounds
Adjunct to [cholinesterase inhibitors](/entities/cholinesterase-inhibitors)

Earlier Intervention

Trials in preclinical AD (anti-amyloid in asymptomatic individuals)
Use of genetic risk scores for patient selection
Prevention trials in carriers of deterministic mutations (e.g., [APP](/entities/app-protein), PSEN1)

Ongoing Studies

Clarity-OLE: Open-label extension studying long-term safety and efficacy
AHEAD 3-45: Prevention trial in preclinical AD
[DIAN](/entities/dian-study): Targeting dominantly inherited Alzheimer's

AAIC 2026 Updates

For comprehensive coverage of lecanemab data presented at AAIC 2026, including long-term safety and efficacy data from the Clarity-OLE open-label extension, real-world effectiveness data, and new analyses on ARIA management protocols, see: [AAIC 2026: Immunotherapy and Antibody Therapeutics Update](/events/aaic-2026/immunotherapy-update)

Background

The study of Lecanemab (Leqembi) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[Leqembi Official Website](https://www.leqembi.com)
[ClinicalTrials.gov: Lecanemab](https://clinicaltrials.gov/search?term=Lecanemab)
[Eisai Product Information](https://www.eisai.com)
[Biogen Alzheimer's Disease Portfolio](https://www.biogen.com)

References

[McDade, E., et al. (2022). Lecanemab in patients with early Alzheimer's Disease: detailed results on biomarker, cognitive, and clinical efficacy. Alzheimer's & Dementia, https://doi.org/10.1002/alz.12653 (2022)](https://doi.org/10.1002/alz.12653](https://doi.org/10.1002/alz.12653](https://doi.org/10.1002/alz.12653)

[Ishii, M., et al. (2022). Lecanemab: A Novel Anti-Amyloid Monoclonal Antibody for Alzheimer's Disease. Journal of Alzheimer's Disease, https://doi.org/10.3233/JAD-220858 (2022)](https://doi.org/10.3233/JAD-220858](https://doi.org/10.3233/JAD-220858](https://doi.org/10.3233/JAD-220858)

[van Dyck, C.H., et al. (2023). Lecanemab in Early Alzheimer's Disease. The New England Journal of Medicine, https://doi.org/10.1056/NEJMoa2212948 (2023)](https://doi.org/10.1056/NEJMoa2212948](https://doi.org/10.1056/NEJMoa2212948](https://doi.org/10.1056/NEJMoa2212948)

[Cummings, J., et al. (2022). Lecanemab: A Review of Its Use in Alzheimer's Disease. Neurology and Therapy, https://doi.org/10.1007/s40120-022-00345-7 (2022)](https://doi.org/10.1007/s40120-022-00345-7](https://doi.org/10.1007/s40120-022-00345-7](https://doi.org/10.1007/s40120-022-00345-7)

Unknown, Eisai Co., Ltd. (2022). Lecanemab Clarity-AD Topline Results. Press Release (2022)

[Sperling, R.A., et al. (2023). Amyloid-related imaging abnormalities in the Clarity-AD trial. Alzheimer's & Dementia, https://doi.org/10.1002/alz.12795 (2023)](https://doi.org/10.1002/alz.12795](https://doi.org/10.1002/alz.12795](https://doi.org/10.1002/alz.12795)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR
[Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — 0.51 · Target: APOE
[Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — 0.46 · Target: APOE
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-lecanemab

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-lecanemab
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6c3bcbd552d2
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-lecanemab'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

58

Outgoing

92

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Lecanemab (Leqembi)

Lecanemab (Leqembi)

Lecanemab (Leqembi)

Overview

Introduction

Mechanism of Action

Amyloid-Beta Targeting

Clearance Mechanisms

Clinical Development

Phase II Clinical Trial (Study 201)

Phase III Clarity Trial

Efficacy

Cognitive Outcomes

Biomarker Effects

Subgroup Analyses

Safety Profile

ARIA Monitoring Guidelines

Other Adverse Events

Comparison with Other Anti-Amyloid Therapies

Regulatory Status

Approvals

Indication

Future Directions

Combination Therapies

Earlier Intervention

Ongoing Studies

AAIC 2026 Updates

Background

Allen Brain Atlas Resources

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Lecanemab (Leqembi)

Lecanemab (Leqembi)

Lecanemab (Leqembi)

Overview

Introduction

Mechanism of Action

Amyloid-Beta Targeting

Clearance Mechanisms

Clinical Development

Phase II Clinical Trial (Study 201)

Phase III Clarity Trial

Efficacy

Cognitive Outcomes

Biomarker Effects

Subgroup Analyses

Safety Profile

Amyloid-Related Imaging Abnormalities (ARIA)[@sperling2023]

ARIA Monitoring Guidelines

Other Adverse Events

Comparison with Other Anti-Amyloid Therapies

Regulatory Status

Approvals

Indication

Future Directions

Combination Therapies

Earlier Intervention

Ongoing Studies

AAIC 2026 Updates

Background

Allen Brain Atlas Resources

See Also

External Links

References

Related Hypotheses

💬 Discussion